Seizures and epilepsy in oncological practice: Causes, course, mechanisms and treatment

Journal of Neurology, Neurosurgery and Psychiatry

Volumn 78, Issue 4, 2007, Pages 342-349

  Singh, Gagandeep ^b   Rees, Jeremy H ^a   Sander, Josemir W ^a  

^a NATIONAL HOSPITAL FOR NEUROLOGY AND NEUROSURGERY   (United Kingdom)

^b DAYANAND MEDICAL COLLEGE AND HOSPITAL   (India)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; ANTICONVULSIVE AGENT;

BRAIN METASTASIS; CANCER PATIENT; CEREBROVASCULAR DISEASE; DISEASE COURSE; EPILEPSY; HUMAN; METABOLIC DISORDER; PARANEOPLASTIC SYNDROME; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SEIZURE; INCIDENCE; NEOPLASM; PATHOPHYSIOLOGY;

ANTICONVULSANTS; ANTINEOPLASTIC AGENTS; HUMANS; INCIDENCE; NEOPLASMS; SEIZURES;

EID: 33947721909     PISSN: 00223050     EISSN: 1468330X     Source Type: Journal    
DOI: 10.1136/jnnp.2006.106211     Document Type: Review

References (82)

1. Sander JW. The epidemiology of epilepsy revisited. Curr Opin Neurol 2003;16:165-70.
2. Hauser WA, Hesdorffer DC. Epilepsy: frequency, causes and consequences. New York: Demos Publications, 1990:7-9.
3. Office for National Statistics, Registration. Registrations for cancer diagnosed in 2001, Series MBI No.32. London: National Statistics 2004, http:/www.statistics.gov.uk.
4. Singh G, Driever PH, Sander JW. Cancer risk in people with epilepsy: the role of antiepileptic drugs. Brain 2005;128:7-17.
5. Shuper A, Yaniv I, Michowitz S, et al. Epilepsy associated with pediatric brain tumors: the neuro-oncologic perspective. Pediatr Neurol 2003;29:232-5.
6. Hildebrand J, Lecaille C, Perennes J, et al. Epileptic seizures during follow-up of patients treated for primary brain tumors. Neurology 2005;65:212-15.
7. Clouston PD, DeAngelis LM, Posner JB. The spectrum of neurological disease in patients with systemic cancer. Ann Neurol 1992;31:268-73.
8. DiMario Jr FJ, Packer RJ. Acute mental status changes in children with systemic cancer. Pediatrics 1990;85:353-60.
9. Ochs JJ, Ching-Hong Pui, Mason C, et al. Seizures in childhood lymphoblastic leukaemia patients. Lancet 1984:1422-4.
10. Matyal J, Grossman R, Yusuf FH, et al. Prognosis and treatment of seizures in children with acute lymphoblastic leukemia. Epilepsia 1995;36:831-6.
11. Antunes NL. Seizures in children with systemic cancer. Pediatr Neurol 2003;28:190-3.
12. Mavrakis AN, Halpern EF, Barker FG II, et al. Diagnostic evaluation of patients with a brain mass as the presenting manifestation of cancer. Neurology 2005;65:908-11.
13. Posner JB. Management of central nervous system metastases. Semin Oncol 1977;4:81-91.
14. Nussbaum ES, Djalilian MR, Cho KM, et al. Brain metastases. Histology, multiplicity, surgery, and survival. Cancer 1996;78:1781-8.
15. Wasserstrom WR, Glass JP, Posner JB. Diagnosis and treatment of leptomeningeal metastases from solid tumors: experience with 90 patients. Cancer 1982;49:759-72.
16. Patchell RA, Tibbs PA, Walsh JW. A randomised trial of surgery in the treatment of single metastasis to the brain. N Engl J Med 1990;322:494-500.
17. Olivi A, Grossman SA, Tatter S, et al. Dose escalation of carmustine in surgically implanted polymers in patients with recurrent malignant glioma: new approaches to brain tumor therapy CNS consortium trial. J Clin Oncol 2003;21:1845-9.
18. Yeh KH, Cheng AL. High-dose 5-fluorouracil infusional therapy is associated with hyperammonaemia, lactic acidosis and encephalopathy. Br J Cancer 1997;75:464-5.
19. Pirzada NA, Ali II, Dafer RM. Fluorouracil-induced neurotoxicity. Ann Pharmacother 2000;34:35-8.
20. Steeghs N, de Jongh FE, Sillevis Smitt PA, et al. Cisplatin-induced encephalopathy and seizures. Anticancer Drugs 2003;14:443-6.
21. Lyass O, Lossos A, Hubert A, et al. Cisplatin-induced non-convulsive encephalopathy. Anticancer Drugs 1998;9:100-4.
22. Morris ME. Brain and CSF magnesium concentrations during magnesium deficit in animals and humans: neurological symptoms. Magnes Res 1992;5:303-13
23. McEvoy GK, ed. American hospital formulary service, drug information. Bethesda: American Society of Hospital Pharmacists, 1992.
24. National Drug Information Service. NDIS profile on cisplatin. Canberra: Commonwealth Department of Human Services and Health, 1985.
25. Dropcho EJ, Rosenfeld SS, Vitek J, et al. Phase II study of intracarotid or selective intracerebral infusion of cisplatin for treatment of recurrent anaplastic gliomas. J Neurooncol 1998;36:191-8.
26. Vassal G, Deroussent A, Hartmann O, et al. Dose-dependent neurotoxicity of high-dose busulfan in children: a clinical and pharmacological study. Cancer Res 1990;50:6203-7.
27. La Morgia C, Mondini S, Guarino M, et al. Busulfan neurotoxicity and EEG abnormalities: a case report. Neurol Sci 2004;25:95-7.
28. Williams SA, Makker SP, Grupe WE. Seizures: a significant side effect of chlorambucil therapy in children. J Pediatr 1978;93:516-18.
29. Byrne TN Jr, Moseley TA III, Finer MA. Myoclonic seizures following chlorambucil overdose. Ann Neurol 1981;9:191-4.
30. Hook CC, Kimmel DW, Kvols LK, et al. Multifocal inflammatory leukoencephalopathy with 5-fluorouracil and levamisole. Ann Neurol 1992;31:262-7.
31. van Kuilenburg AB, De Abreu RA, van Gennip AH. Pharmacogenetic and clinical aspects of dihydropyrimidine dehydrogenase deficiency. Ann Clin Biochem 2003;40:41-5.
32. van Kuilenburg AB. Dihydropyrimidine dehydrogenase and the efficacy and toxicity of 5-fluorouracil. Eur J Cancer 2004;40:939-50.
33. Lazar A, Mau-Holzmann UA, Kolb H, et al. Multiple organ failure due to 5-fluorouracil chemotherapy in a patient with a rare dihydropyrimidine dehydrogenase gene variant. Onkologie 2004;27:559-62.
34. Finkelstein Y, Zevin S, Heyd J, et al. Emergency treatment of life-threatening intrathecal methotrexate overdose. Neurotoxicology 2004;25:407-10.
35. Rollins N, Winick N, Bash R, et al. Acute methotrexate neurotoxicity: findings on diffusion-weighted imaging and correlation with clinical outcome. Am J Neuroradiol 2004;25:1688-95.
36. Lovblad K, Kelkar P, Ozdoba C, et al. Pure methotrexate encephalopathy presenting with seizures: CT and MRI features. Pediatr Radiol 1998;28:86-91.
37. Bleyer WA, Griffin TW. White matter necrosis, mineralizing microangiopathy, and intellectual abilities in survivors of childhood leukemia: association with central nervous system irradiation and methotrexate therapy. In: Gilbert HA, Kagan AR, eds. Radiation damage to the nervous system. New York: Raven Press, 1980:155-74.
38. Ball WS, Prenger EC, Ballard ET. Neurotoxicity of radio/chemotherapy in children: pathologic and MR correlation. Am J Neuroradiol 1998;13:761-76.
39. Aur RJA, Simone JV, Verzosa MS, et al. Childhood lymphocytic leukaemia - study VIII. Cancer 1978;42:2123-34.
40. Price RA, Birdwell DA. The central nervous system in childhood leukaemia. III. Mineralizing microangiopathy and dystrophic calcification. Cancer 1978;42:717-28.
41. Legroux-Crespel E, Lafaye S, Mahe E, et al. Seizures during interferon alpha therapy: three cases in dermatology. Ann Dermatol Venereol 2003;130:202-4.
42. Pavlovsky L, Seiffert E, Heinemann U, et al. Persistent BBB disruption may underlie alpha interferon-induced seizures. J Neurol 2005;252:42-6.
43. Brouwers PJ, Bosker RJI, Ron Schaafsma MR, et al. Photosensitive seizures associated with interferon-alfa-2a. Ann Pharmacother 1999;33:113-4.
44. Gleeson JG, du Plessis AJ, Barnes PD, et al. Cyclosporin A acute encephalopathy and seizure syndrome in childhood: clinical features and risk of seizure recurrence. J Child Neurol 1998;13:336-44.
45. Zakrzewski JL. Cyclosporin A-associated status epilepticus related to haematopoietic stem cell transplantation for thalassemia. Pediatr Hematol Oncol 2003;20:481-6.
46. Faraci M, Lanino E, Dallorso S, et al. Mesial temporal sclerosis - a late complication in four allogeneic paediatric recipients with persistent seizures after an acute episode of cyclosporine-a neurotoxicity. Bone Marrow Transplant 2003;31:919-22.
47. Goyal M, Bangert BA, Wiznitzer M. Mesial temporal sclerosis in acute childhood leukemias. Epilepsia 2003;44:131-4.
48. Gijtenbeek JM, van den Bent MJ, Vecht CJ. Cyclosporine neurotoxicity: a review. J Neurol 1999;246:339-46.
49. Serkova NJ, Christians U, Benet LZ. Biochemical mechanisms of cyclosporine neurotoxicity. Mol Interv 2004;4:97-107.
50. Wen PW. Central nervous system complications of cancer therapy. In: Schiff D, Wen PW, eds. Cancer neurology in clinical practice. Totowa, NJ: Human Press, 2003:253-72.
51. Dropcho EJ. Neurotoxicity of cancer chemotherapy. Semin Neurol 2004;24:419-26.
52. Karadeniz C, Oguz A, Canter B, et al. Incidence of seizures in paediatric cancer patients treated with imipenem/cilastatin. Pediatr Hematol Oncol 2000;17:585-90.
53. Sharma A, Raina V. Generalised seizures following ondansetron. Ann Oncol 2001;12:131-2.
54. Pratt CB, Douglass EC, Kovnar EH, et al. A phase I study of ifosfamide given on alternate days to treat children with brain tumours. Cancer 1993;71:3666-9.
55. Salido M, Macarron P, Hernandez-Garcia C, et al. Water intoxication induced by low dose cyclophosphamide in the patients with systemic lupus erythematosus. Lupus 2003;2:636-9.
56. MacIsaac RJ, Seeman E, Jerums G. Seizures after alendronate. J R Soc Med 2002;95:615-16.
57. Graves TO, Gandhi S, Smith SJ, et al. Misdiagnosis of seizures: insulinoma presenting as adult-onset seizure disorder. J Neurol Neurosurg Psychiatry 2004;75:1091-2.
58. Leiba A, Bar-Dayan Y, Leker RR, et al. Seizures as a presenting symptom of phaeochromocytoma in a young soldier. J Hum Hypertens 2003;17:73-5.
59. Gultekin SH, Rosenfeld MR, Voltz R, et al. Paraneoplastic limbic encephalitis: neurological symptoms, immunological findings and tumour association in 50 patients. Brain 2000;123:1481-94.
60. Ahern GL, O'Connor M, Dalmau J, et al. Paraneoplastic temporal lobe epilepsy with testicular neoplasm and atypical amnesia. Neurology 1994;44:1270-4.
61. Shavit YB, Graus F, Probst A, et al. Epilepsia partialis continua: a new manifestation of anti-Hu-associated paraneoplastic encephalomyelitis. Ann Neurol 1999;45:225-58.
62. Graus F, Rogers LR, Posner JB. Cerebrovascular complications in patients with cancer. Medicine (Baltimore), 1985;64:16-35.
63. Cestari DM, Weine DM, Panageas KS, et al. Stroke in patients with cancer: incidence and etiology. Neurology 2004;62:2025-30.
64. Bushman JE, Palmieri D, Whinna HC, et al. Insight into the mechanism of asparaginase-induced depletion of antithrombin III in treatment of childhood acute lymphoblastic leukaemia. Leuk Res 2000;24:559-65.
65. Beristain X, Azzarelli B. The neurological masquerade of intravascular lymphomatosis. Arch Neurol 2002;59:439-43.
66. Gordon LI, Kwaan HC. Thrombotic microangiopathy manifesting as thrombotic thrombocytopenic purpura/hemolytic uremic syndrome in the cancer patient. Semin Thromb Hemost 1999;25:217-21.
67. Pruitt AA. Central nervous system infections in cancer patients. Semin Neurol 2004;24:435-52.
68. Wainwright MS, Martin PL, Morse RP, et al. Human herpesvirus 6 limbic encephalitis after stem cell transplantation. Ann Neurol 2001;50:612-19.
69. Fujino Y, Nakajima M, Inoue H, et al. Human herpesvirus 6 encephalitis associated with hypersensitivity syndrome. Ann Neurol 2002;51:771-4.
70. Reutens DC, Dubeau F, Melanson D, et al. Intractable partial epilepsy following low-dose scalp irradiation in infancy. Ann Neurol 1995;38:951-4.
71. Bhansali A, Banerjee AK, Chanda A, et al. Radiation-induced brain disorders in patients with pituitary tumours. Australas Radiol 2004;48:339-46.
72. Woo E, Lam K, Yu YL, et al. Temporal lobe and hypothalamic-pituitary dysfunctions after radiotherapy for nasopharyngeal carcinoma: a distinct clinical syndrome. J Neurol Neurosurg Psychiatry 1988;51:1302-7.
73. Baumgartner JE, Ater JL, Ha CS, et al. Pathologically proven cavernous angiomas of the brain following radiation therapy for paediatric brain tumours. Pediatr Neurosurg 2003;39:201-7.
74. Reiling MV, Pui Ching-Hon, Sandlund JT, et al. Adverse effect of anticonvulsants on efficacy of chemotherapy for acute lymphoblastic leukaemia. Lancet 2000;356:285-90.
75. Ahmed I, Reichenberg J, Lucas A, et al. Erythema multiforme associated with phenytoin and craniarradiation therapy: a report of three patients and review of the literature. Int J Dermatol 2004;43:67-73.
76. Bourg V, Lebrun C, Chichmanian RM, et al. Nitroso-urea-cisplatin-based chemotherapy associated with valproate: increase of haematological toxicity. Ann Oncol 2001;12:217-19.
77. Hassan M, Oberg G, Bjorkholm M, et al. Influence of prophylactic anticonvulsant therapy on high-dose busulphan kinetics. Cancer Chemother Pharmacol 1993;33:181-6.
78. Meloni G, Nasta L, Pinto RM, et al. Clonazepam prophylaxis and busulfan-related myoclonic epilepsy in autografted acute leukaemia patients. Haematologica 1995;80:532-4.
79. Schwarer AP, Opat SS, Watson AL, et al. Clobazam for seizure prophylaxis during busulfan chemotherapy. Lancet 1995;346:1238.
80. Chan KW, Mullen CA, Worth LL, et al. Lorazepam for seizure prophylaxis during high-dose busulfan administration. Bone Marrow Transplant 2002;29:963-5.
81. Rabinowicz AL, Hinton DR, Dyck P, et al. High-dose tamoxifen in treatment of brain tumors: interaction with antiepileptic drugs. Epilepsia 1995;36:513-15.
82. Glantz MJ, Cole BF, Forsyth PA, et al. Practice parameter: anticonvulsant prophylaxis in patients with newly diagnosed brain tumours. Report of Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2000;54:1886-93.